ES2192588T3 - 4-(arilaminometilen)-2,4-dihidro-pirazol-3-onas. - Google Patents

4-(arilaminometilen)-2,4-dihidro-pirazol-3-onas.

Info

Publication number
ES2192588T3
ES2192588T3 ES96107518T ES96107518T ES2192588T3 ES 2192588 T3 ES2192588 T3 ES 2192588T3 ES 96107518 T ES96107518 T ES 96107518T ES 96107518 T ES96107518 T ES 96107518T ES 2192588 T3 ES2192588 T3 ES 2192588T3
Authority
ES
Spain
Prior art keywords
sup
sub
rent
atomos
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96107518T
Other languages
English (en)
Inventor
Michael Dr Arlt
Rochus Dr Jonas
Maria Christadler
Gunter Schneider
Michael Dr Klockow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2192588T3 publication Critical patent/ES2192588T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

LA INVENCION TRATA DE DERIVADOS DE LA DL 2 PIRAZOLINONA-5 DE FORMULA GENERAL I: EN DONDE R{SUP,1} ES BENZILO, ALCOXIBENZILO CON 1 - 3 ATOMOS DE C EN LA PARTE ALQUILICA, FENILO, FENILO SUSTITUIDO DE UNA A TRES VECES CON AMINO, ACILO, HALOGENO, NITRO, CN, AO-, CARBOXILO, SULFONILO, A-O-CO-, A-CO-NH-, A-CO-NA-, CARBAMOILO, N-ALQUILCARBAMOILO, N,NDIALQUILCARBAMOILO (CON 1 - 6 ATOMOS DE C EN LA PARTE ALQUILICA, A-O-CO-NH-, A-C-CO-NA-, SO{SUB,2}NR{SUP,4}R{SUP,5} (R{SUP,4} Y R{SUP,5} PUEDEN SER H O ALQUILO CON 1 - 6 ATOMOS DE C, O NR{SUP,4}R{SUP,5} UN CICLO DE 5 O 6 MIEMBROS, QUE PUEDE ESTAR SUSTITUIDO CON OTROS HETEROATOMOS COMO N, S, O O POR A) A-CO-NHSO{SUB,2}-, A-CO-NA-SO{SUB,2}-, A-SO{SUB,2}-NH-, A-SO{SUB,2}-NA-, (A-SO{SUB,2}-){SUB,2}N-, TETRAZOLILO, O FOSFONILO; O PIRIDILO; R{SUP,2} ES ALQUILO CON 1 - 5 ATOMOS DE C, ALCOXICARBONILALQUILO, HIDROXIALQUILO, HIDROXICARBONILALQUILO; R{SUP,3} ES H, ALQUILO CON 1 - 5 ATOMOS DE C DE CADENA LINEAL O RAMIFICADA, ALCOXILO CON 1- 5 ATOMOS DE C DE CADENALINEAL O RAMIFICADA; O ALQUILO, AMINOALCANOILO, AMINOALQUILO, CARBAMOILO, SO{SUB,2}NR{SUP,4}R{SUP,5} QUE PUEDEN ESTAR SUSTITUIDOS CON FLUOR O CLORO (R{SUP,4}Y R{SUP,5} PUEDEN SER H, ALQUILO CON 1 - 6 ATOMOS DE C O NR{SUP,4}R{SUP,5} FORMAR UN CICLO DE 5 O 6 MIEMBROS, QUE PUEDE ESTAR SUSTITUIDO CON OTROS HETEROATOMOS COMO N, S, O O CON A); A ES UN ALQUILO CON 1 - 6 ATOMOS DE C DE CADENA LINEAL O RAMIFICADA, O ESTE ALQUILO SUSTITUIDO CON FLUOR O CLORO; Y SUS SALES FISIOLOGICAMENTE ACEPTABLES. UNA PARTE DE LA INVENCION SON TAMBIEN LOS PROCEDIMIENTOS PARA LA OBTENCION DE ESTOS COMPUESTOS, Y SU UTILIZACION COMO INHIBIDORES SELECTIVOS DE LAS FOSFODIESTERASAS ESPECIFICAS DE LA CGMP (CGMP PDE) Y COMPUESTOS FARMACEUTICAMENTE EFECTIVOS.
ES96107518T 1995-05-17 1996-05-10 4-(arilaminometilen)-2,4-dihidro-pirazol-3-onas. Expired - Lifetime ES2192588T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19518082A DE19518082A1 (de) 1995-05-17 1995-05-17 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one

Publications (1)

Publication Number Publication Date
ES2192588T3 true ES2192588T3 (es) 2003-10-16

Family

ID=7762136

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96107518T Expired - Lifetime ES2192588T3 (es) 1995-05-17 1996-05-10 4-(arilaminometilen)-2,4-dihidro-pirazol-3-onas.

Country Status (22)

Country Link
US (1) US5869516A (es)
EP (1) EP0743304B1 (es)
JP (1) JP3996656B2 (es)
KR (1) KR100413154B1 (es)
CN (1) CN1066138C (es)
AT (1) ATE235469T1 (es)
AU (1) AU713042B2 (es)
CA (1) CA2176649C (es)
CZ (1) CZ291572B6 (es)
DE (2) DE19518082A1 (es)
DK (1) DK0743304T3 (es)
ES (1) ES2192588T3 (es)
HU (1) HUP9601328A3 (es)
NO (1) NO306777B1 (es)
PL (1) PL186049B1 (es)
PT (1) PT743304E (es)
RU (1) RU2180659C2 (es)
SI (1) SI0743304T1 (es)
SK (1) SK284295B6 (es)
TW (1) TW349093B (es)
UA (1) UA59330C2 (es)
ZA (1) ZA963918B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
DE19642284A1 (de) * 1996-10-14 1998-04-16 Merck Patent Gmbh Pyrazolinone zur Behandlung von Potenzstörungen
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
DE19807423A1 (de) * 1998-02-21 1999-08-26 Hoechst Marion Roussel De Gmbh Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
KR20060005375A (ko) * 2003-04-18 2006-01-17 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제로서의 피라졸 유도체
EP1799673A1 (en) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AU2005312585B2 (en) * 2004-12-08 2012-01-12 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
JP4973192B2 (ja) * 2004-12-14 2012-07-11 日産化学工業株式会社 アミド化合物及びトロンボポエチンレセプター活性化剤
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
TW200730518A (en) * 2005-10-12 2007-08-16 Sicor Inc Crystalline forms of docetaxel and processes for their preparation
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2000176A1 (en) * 2007-06-04 2008-12-10 GenKyo Tex Tetrahydroindole derivatives as NADPH Oxidase inhibitors
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
SG11201606149YA (en) 2014-02-14 2016-09-29 Inception 2 Inc Pyrazolone compounds and uses thereof
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
WO2021194893A1 (en) 2020-03-24 2021-09-30 Cyrano Therapeutics, Inc. Treatment of chemosensory dysfunction from a coronavirus infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905997A (en) * 1974-06-21 1975-09-16 Warner Lambert Co 3-Aryl-5-oxo-2-pyrazoline-4-carboxanilides and process therefor
US4355159A (en) * 1979-05-23 1982-10-19 Ciba-Geigy Corporation Nickel complex pigments of azines
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
DK169672B1 (da) * 1985-05-20 1995-01-09 Mitsubishi Chem Ind Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater
DE3728278A1 (de) * 1986-12-17 1988-06-23 Bayer Ag Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten
US5162528A (en) * 1986-12-17 1992-11-10 Bayer Aktiengesellschaft Herbicidal and fungicidal agents based on substituted pyrazolin-5-one derivatives
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
DE4130833A1 (de) * 1991-09-17 1993-03-18 Bayer Ag Diarylpyrazolinone
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one

Also Published As

Publication number Publication date
CN1066138C (zh) 2001-05-23
RU2180659C2 (ru) 2002-03-20
NO306777B1 (no) 1999-12-20
SK284295B6 (sk) 2005-01-03
ZA963918B (en) 1996-11-25
NO961996D0 (no) 1996-05-15
DE59610254D1 (de) 2003-04-30
CN1141291A (zh) 1997-01-29
HUP9601328A2 (en) 1997-02-28
KR960041166A (ko) 1996-12-19
SI0743304T1 (en) 2003-10-31
AU5225396A (en) 1996-11-28
ATE235469T1 (de) 2003-04-15
EP0743304A1 (de) 1996-11-20
PL314286A1 (en) 1996-11-25
PT743304E (pt) 2003-08-29
CA2176649A1 (en) 1996-11-18
EP0743304B1 (de) 2003-03-26
SK58996A3 (en) 1996-12-04
AU713042B2 (en) 1999-11-25
TW349093B (en) 1999-01-01
CZ291572B6 (cs) 2003-04-16
DE19518082A1 (de) 1996-11-21
HU9601328D0 (en) 1996-07-29
US5869516A (en) 1999-02-09
JP3996656B2 (ja) 2007-10-24
CA2176649C (en) 2008-08-05
CZ142196A3 (en) 1997-01-15
NO961996L (no) 1996-11-18
PL186049B1 (pl) 2003-09-30
UA59330C2 (uk) 2003-09-15
HUP9601328A3 (en) 1999-04-28
DK0743304T3 (da) 2003-07-14
JPH08311035A (ja) 1996-11-26
KR100413154B1 (ko) 2004-05-12

Similar Documents

Publication Publication Date Title
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
ES2084944T3 (es) Amidas terapeuticas.
MX9707453A (es) Derivados de quinazolina.
ES2053451T3 (es) Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
UY28040A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos.
ES2181803T3 (es) Acidos 4-biarilbutiricos o 5-biarilpentanoicos sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz.
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
UY27338A1 (es) Nuevos derivados de ácido sulfónico
FI981956A0 (fi) 2-(4-hydroksipiperidino)-1-alkanolijohdannaisia verettömyyden vastaisia aineina
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
ES2067874T3 (es) Derivados de acetamida.
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
ES2121597T3 (es) Derivados de bencenosulfonamida para el tratamiento de la inestabilidad de la vejiga.
MX9205123A (es) Derivados de 5-hidroxi-2-pirimidinilmetileno utiles como agentes anti-inflamatorios.
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
UY27034A1 (es) Derivados de pirimidina
ES2052593T3 (es) Procedimiento para preparar derivados del indano.
ES470296A1 (es) Mejoras introducidas en un procedimiento para la preparacionde fluormetal-aminoacidos
ES2182090T3 (es) Nuevos derivados de pirrol.
AR026350A1 (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa vii
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina